CryoPort Achieves Historic ISO Certification for Temperature-Controlled Supply Chain Solutions in Life Sciences

Cryoport Achieves Groundbreaking ISO Certification in Temperature-Controlled Supply Chain Solutions

Cryoport, Inc., a frontrunner in temperature-controlled supply chain solutions for the life sciences sector, reaches a significant milestone by obtaining ISO 21973:2020 certification through its Cryoport Systems division. This certification marks a historic achievement as it is the first of its kind within the global supply chain solutions market, establishing comprehensive standards for the safe transportation of human cells used in advanced therapies. With the cell and gene therapy industry rapidly expanding, the need for rigorous safety and integrity protocols is paramount, and Cryoport's certification addresses these critical requirements.

The ISO 21973 standard, developed with substantial input from Cryoport Systems since its inception in 2020, provides essential guidelines for managing environmental control, logistics, and data handling during the transportation of therapeutic cells. Any deviation from these protocols can severely impact patient outcomes, making adherence to these standards vital. Cryoport's proprietary Chain of Compliance® has long conformed to these rigorous standards, and the successful attainment of this certification underscores the company’s commitment to minimizing risks such as temperature excursions and contamination during the supply chain process.

Jerrell Shelton, Chairman and CEO of Cryoport, articulates that this certification not only solidifies the company's pioneering role in the life sciences industry but also enhances its reputation for excellence, particularly in light of the recent recognition with the 2025 CPHI Award for Supply Chain Excellence. While the ISO 21973 standard is primarily tailored for regenerative medicine, its applicability extends to various other life sciences sectors, including reproductive medicine and animal health, further broadening Cryoport's impact in the industry.

In addition to this certification, Cryoport continues to equip stakeholders with resources to understand the implications of ISO 21973 for regenerative medicine supply chains. The company invites interested parties to visit its website or download a whitepaper that delves deeper into the standard and its significance within the context of modern therapies.

Through this milestone, Cryoport not only reinforces its leadership position in temperature-controlled logistics but also contributes to the overall enhancement of safety and efficacy in the life sciences field, promoting better patient outcomes across multiple therapeutic areas.